
Sarepta's bad week raised questions about its gene therapy program. Here are some answers
- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
Sarepta Therapeutics (SRPT) wasn’t directly implicated in the biotech sector’s credibility crisis last week, but that didn’t stop the company from running into trouble. The “erroneous”
disclosure last Thursday of a serious side effect affecting a single patient with Duchenne muscular dystrophy enrolled in Sarepta’s gene therapy clinical trial sowed confusion, concern, and
anger. The stock price took a hit, recovered, then fell some more. All in, Sarepta shares lost 14%. Monday and a new trading week give Sarepta an opportunity to reset, unless lingering
concerns remain about what exactly happened to its Duchenne gene therapy program and why. Here are eight burning questions and a stab at answers. STAT+ Exclusive Story Already have an
account? Log in THIS ARTICLE IS EXCLUSIVE TO STAT+ SUBSCRIBERS UNLOCK THIS ARTICLE — PLUS IN-DEPTH ANALYSIS, NEWSLETTERS, PREMIUM EVENTS, AND NEWS ALERTS. Already have an account? Log in
Individual plans Group plans View All Plans To read the rest of this story subscribe to STAT+. Subscribe